Contact this trialFirst, we need to learn more about you.
Cabozantinib + Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 2
Chicago, Illinois
This trial assesses combo therapy of cabozantinib and pembrolizumab to treat metastatic squamous NSCLC after induction with pembrolizumab, carboplatin and nab/paclitaxel. It looks at efficacy, safety and quality of life.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.